Cargando…
Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
Leiomyosarcoma is a heterogeneous tumor group, representing <1% of all new cancers diagnosed in United States. Treatment choice is based upon site, grade, and extent of disease. However, prognosis for metastatic or unresectable sarcoma is very poor with reported median survival of 12 months. Resp...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290122/ https://www.ncbi.nlm.nih.gov/pubmed/22408374 http://dx.doi.org/10.4137/CMO.S7194 |